The "CABA stock forecast 2025" is drawing attention as analysts expect potential price volatility driven by biotech sector trends. Current market sentiment indicates CABA could trade in the $18–25 range if R&D milestones are met, especially with clinical trial updates likely affecting earnings per share (EPS) projections. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. Although the company has no approved products, it continues to advance its portfolio, with notable updates on NTLA-2001 and NTLA-2002. The biotech sector’s innovation cycle directly impacts "CABA stock forecast 2025", as momentum traders look for technical setups over $20 resistance levels. Continued favorable moving average trends may sustain bullish sentiment into mid-year.
